

amb C37 57. The method of claim 55, wherein the cell comprises an exogenous nucleic acid encoding TSP-2 or a functional fragment or analog thereof.

9/20/01 58. The method of claim 55, wherein the cell is autologous.

59. The method of claim 56, wherein the cell is autologous.

60. The method of claim 57, wherein the cell is autologous.

61. The method of claim 55, wherein the cell is allogeneic.

B2 62. The method of claim 56, wherein the cell is allogeneic.

63. The method of claim 57, wherein the cell is allogeneic.

64. The method of claim 55, wherein the cell is xenogeneic.

65. The method of claim 56, wherein the cell is xenogeneic.

66. The method of claim 57, wherein the cell is xenogeneic.

67. The method of claim 56, wherein the promoter of the endogenous TSP-2 gene has been replaced by a promoter from another gene.

68. The method of claim 54, 55, 56 or 57, wherein the cell is an epithelial cell.

69. The method of claim 54, 55, 56 or 57, wherein the cell is selected from the group consisting of: a fibroblast, a keratinocyte, an endothelial cell, a glial cell, a neural cell, a lymphocyte, a bone marrow cell, and a muscle cell.

70. The method of claim 55, wherein the level of TSP-2 in the subject after administration is increased for at least 2 days.

71. The method of claim 55, wherein the level of TSP-2 in the subject after administration is increased for at least 10 days.

72. The method of claim 55, wherein the level of TSP-2 in the subject after administration is increased for at least 14 days.

B2 73. The method of claim 55, wherein the level of TSP-2 in the subject after administration is increased for at least 30 days.

74. The method of claim 54, 55, 56 or 57, wherein the disorder is characterized by pre-cancerous, cancerous or neoplastic cells.

75. The method of claim 74, wherein the disorder is selected from the group consisting of: melanoma, prostate cancer, breast cancer, colon cancer, and lung cancer.

76. The method of claim 54, wherein the subject is a human.

77. The method of claim 55, wherein the subject is a human.

78. The method of claim 56, wherein the subject is a human.

79. The method of claim 57, wherein the subject is a human.

80. The method of claim 54, 55, 56 or 57, wherein the disorder is selected from the group consisting of: psoriasis, rheumatoid arthritis, multiple sclerosis, diabetic retinopathy, and restenosis after coronary angioplasty.